The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...
Geron Corporation's RYTELO gains FDA approval for Low-Risk MDS, with strong sales projections and promising Phase 3 study.
A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that ...
The study highlights poor outcomes for leukaemia patients with a history of myelodysplastic syndrome treatment and related ...
The Hearty Soul on MSN3d
Man Devastated After Discovering He Was Never Diagnosed with Cancer Despite 9 Years of ChemotherapyAnthony Olson, a then-33-year-old man from Helena, Montana, received devastating news from Dr. Thomas C. Weiner, a former oncologist at St. Peter's Health. Olson was told he had Myelodysplastic ...
The following is a summary of “Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation,” published in the December ...
Panelists discuss key learnings from recent studies on lower-risk myelodysplastic syndrome (LR-MDS) treatment, identify ...
Trecondyv is under clinical development by medac and currently in Pre-Registration for Myelodysplastic Syndrome.
The FDA granted Rigel Pharmaceuticals (RIGL) orphan status for its treatment of myelodysplastic syndromes.Stay Ahead of the Market:Discover ...
H.C. Wainwright reaffirmed its Buy rating and $25.00 price target on shares of Innate Pharma (EPA:IPH) S.A. (NASDAQ:IPHA), ...
Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results